{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T20:49:15Z","timestamp":1793566155378,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM109025"],"award-info":[{"award-number":["P20GM109025"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG053798"],"award-info":[{"award-number":["R01AG053798"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P20AG068053"],"award-info":[{"award-number":["P20AG068053"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P30AG072959"],"award-info":[{"award-number":["P30AG072959"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R35AG71476"],"award-info":[{"award-number":["R35AG71476"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["U01NS093334"],"award-info":[{"award-number":["U01NS093334"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s40265-023-01858-9","type":"journal-article","created":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T06:02:01Z","timestamp":1681538521000},"page":"569-576","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":250,"title":["Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8944-4158","authenticated-orcid":false,"given":"Jeffrey","family":"Cummings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,15]]},"reference":[{"issue":"18","key":"1858_CR1","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384(18):1691\u2013704.","journal-title":"N Engl J Med"},{"issue":"1","key":"1858_CR2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-Abeta protofibril antibody. Alzheimers Res Ther. 2021;13(1):80.","journal-title":"Alzheimers Res Ther."},{"key":"1858_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948","author":"CH van Dyck","year":"2022","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2022. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"},{"issue":"2","key":"1858_CR4","first-page":"197","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimer\u2019s Dis. 2022;9(2):197\u2013210.","journal-title":"J Prev Alzheimer's Dis."},{"issue":"1","key":"1858_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13195-021-00838-z","volume":"13","author":"J Cummings","year":"2021","unstructured":"Cummings J, Aisen P, Lemere C, Atri A, Sabbagh M, Salloway S. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimers Res Ther. 2021;13(1):98.","journal-title":"Alzheimers Res Ther."},{"key":"1858_CR6","unstructured":"Writing Group & Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505\u201312."},{"issue":"10","key":"1858_CR7","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1056\/NEJMoa1916945","volume":"383","author":"S Paganoni","year":"2020","unstructured":"Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919\u201330.","journal-title":"N Engl J Med"},{"issue":"3","key":"1858_CR8","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/alz.12450","volume":"18","author":"JL Cummings","year":"2022","unstructured":"Cummings JL, Goldman DP, Simmons-Stern NR, Ponton E. The costs of developing treatments for Alzheimer\u2019s disease: a retrospective exploration. Alzheimers Dement. 2022;18(3):469\u201377.","journal-title":"Alzheimers Dement"},{"issue":"7618","key":"1858_CR9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease. Nature. 2016;537(7618):50\u20136.","journal-title":"Nature"},{"issue":"1","key":"1858_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","volume":"9","author":"S Ostrowitzki","year":"2017","unstructured":"Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease. Alzheimers Res Ther. 2017;9(1):95\u2013110.","journal-title":"Alzheimers Res Ther."},{"key":"1858_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.3392","author":"MJ Pontecorvo","year":"2022","unstructured":"Pontecorvo MJ, Lu M, Burnham SC, Schade AE, Dage JL, Shcherbinin S, et al. Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 2022. https:\/\/doi.org\/10.1001\/jamaneurol.2022.3392.","journal-title":"JAMA Neurol"},{"key":"1858_CR12","unstructured":"Cummings J, Bateman R, Doody R, Salloway S, Black S. Topline results of phase III Graduate I & II pivotal trials with subcutaneous gantenerumab. In: Clinical trials on Alzheimer's disease, San Francisco. 2022."},{"key":"1858_CR13","doi-asserted-by":"publisher","first-page":"o3010","DOI":"10.1136\/bmj.o3010","volume":"379","author":"S Walsh","year":"2022","unstructured":"Walsh S, Merrick R, Richard E, Nurock S, Brayne C. Lecanemab for Alzheimer\u2019s disease. BMJ. 2022;379:o3010.","journal-title":"BMJ"},{"key":"1858_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12959","author":"RC Petersen","year":"2023","unstructured":"Petersen RC, Aisen PS, Andrews JS, Atri A, Matthews BR, Rentz DM, et al. Expectations and clinical meaningfulness of randomized controlled trials. Alzheimers Dement. 2023. https:\/\/doi.org\/10.1002\/alz.12959.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1858_CR15","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s40120-022-00350-y","volume":"11","author":"AA Tahami Monfared","year":"2022","unstructured":"Tahami Monfared AA, Tafazzoli A, Ye W, Chavan A, Zhang Q. Long-term health outcomes of lecanemab in patients with early Alzheimer\u2019s disease using simulation modeling. Neurol Ther. 2022;11(2):863\u201380.","journal-title":"Neurol Ther."},{"issue":"3","key":"1858_CR16","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40120-022-00373-5","volume":"11","author":"AA Tahami Monfared","year":"2022","unstructured":"Tahami Monfared AA, Tafazzoli A, Chavan A, Ye W, Zhang Q. The potential economic value of lecanemab in patients with early Alzheimer\u2019s disease using simulation modeling. Neurol Ther. 2022;11(3):1285\u2013307.","journal-title":"Neurol Ther."},{"issue":"1","key":"1858_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13195-020-00659-6","volume":"12","author":"DB DiBenedetti","year":"2020","unstructured":"DiBenedetti DB, Slota C, Wronski SL, Vradenburg G, Comer M, Callahan LF, et al. Assessing what matters most to patients with or at risk for Alzheimer\u2019s and care partners: a qualitative study evaluating symptoms, impacts, and outcomes. Alzheimers Res Ther. 2020;12(1):90.","journal-title":"Alzheimers Res Ther."},{"issue":"1","key":"1858_CR18","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13195-022-00984-y","volume":"14","author":"SS Assuncao","year":"2022","unstructured":"Assuncao SS, Sperling RA, Ritchie C, Kerwin DR, Aisen PS, Lansdall C, et al. Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14(1):54.","journal-title":"Alzheimers Res Ther."},{"issue":"5580","key":"1858_CR19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353\u20136.","journal-title":"Science"},{"issue":"2","key":"1858_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1042\/BJ20120653","volume":"446","author":"AF Teich","year":"2012","unstructured":"Teich AF, Arancio O. Is the amyloid hypothesis of Alzheimer\u2019s disease therapeutically relevant? Biochem J. 2012;446(2):165\u201377.","journal-title":"Biochem J"},{"issue":"6","key":"1858_CR21","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/alz.12379","volume":"17","author":"E Richard","year":"2021","unstructured":"Richard E, den Brok M, van Gool WA. Bayes analysis supports null hypothesis of anti-amyloid beta therapy in Alzheimer\u2019s disease. Alzheimers Dement. 2021;17(6):1051\u20135.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1858_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/alzrt269","volume":"6","author":"JL Cummings","year":"2014","unstructured":"Cummings JL, Morstorf T, Zhong K. Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014;6(4):37.","journal-title":"Alzheimers Res Ther."},{"issue":"4","key":"1858_CR23","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","volume":"21","author":"E Karran","year":"2022","unstructured":"Karran E, De Strooper B. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat Rev Drug Discov. 2022;21(4):306\u201318.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"1858_CR24","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","volume":"26","author":"H Hampel","year":"2021","unstructured":"Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, et al. The amyloid-beta pathway in Alzheimer\u2019s disease. Mol Psychiatry. 2021;26(10):5481\u2013503.","journal-title":"Mol Psychiatry"},{"issue":"6","key":"1858_CR25","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/nn.4018","volume":"18","author":"ES Musiek","year":"2015","unstructured":"Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space and \u201cwingmen.\u201d Nat Neurosci. 2015;18(6):800\u20136.","journal-title":"Nat Neurosci"},{"issue":"1","key":"1858_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.biopsych.2014.05.006","volume":"77","author":"CM Karch","year":"2015","unstructured":"Karch CM, Goate AM. Alzheimer\u2019s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry. 2015;77(1):43\u201351.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"1858_CR27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s42003-022-03037-0","volume":"5","author":"DL Elbert","year":"2022","unstructured":"Elbert DL, Patterson BW, Lucey BP, Benzinger TLS, Bateman RJ. Importance of CSF-based Abeta clearance with age in humans increases with declining efficacy of blood-brain barrier\/proteolytic pathways. Commun Biol. 2022;5(1):98.","journal-title":"Commun Biol."},{"issue":"4","key":"1858_CR28","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3233\/JAD-215680","volume":"87","author":"A Salehipour","year":"2022","unstructured":"Salehipour A, Bagheri M, Sabahi M, Dolatshahi M, Boche D. Combination therapy in Alzheimer\u2019s disease: is it time? J Alzheimers Dis. 2022;87(4):1433\u201349.","journal-title":"J Alzheimers Dis"},{"key":"1858_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-3-030-05542-4_2","volume":"1118","author":"J Cummings","year":"2019","unstructured":"Cummings J. The role of biomarkers in Alzheimer\u2019s disease drug development. Adv Exp Med Biol. 2019;1118:29\u201361.","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"1858_CR30","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7(4):367\u201385.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"1858_CR31","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen EH, La Joie R, Strom A, Fonseca C, Iaccarino L, Wolf A, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021;20(9):739\u201352.","journal-title":"Lancet Neurol"},{"issue":"8","key":"1858_CR32","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","volume":"21","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele R, van der Kant R, Hansson O. Tau biomarkers in Alzheimer\u2019s disease: towards implementation in clinical practice and trials. Lancet Neurol. 2022;21(8):726\u201334.","journal-title":"Lancet Neurol"},{"issue":"5123","key":"1858_CR33","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science. 1993;261(5123):921\u20133.","journal-title":"Science"},{"issue":"1","key":"1858_CR34","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S1474-4422(20)30412-9","volume":"20","author":"A Serrano-Pozo","year":"2021","unstructured":"Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer\u2019s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 2021;20(1):68\u201380.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1858_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","volume":"79","author":"S Salloway","year":"2022","unstructured":"Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, et al. Amyloid-related imaging abnormalities in 2 Phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 2022;79(1):13\u201321.","journal-title":"JAMA Neurol"},{"issue":"2","key":"1858_CR36","first-page":"221","volume":"9","author":"J Cummings","year":"2022","unstructured":"Cummings J, Rabinovici GD, Atri A, Aisen P, Apostolova LG, Hendrix S, et al. Aducanumab: appropriate use recommendations update. J Prev Alzheimers Dis. 2022;9(2):221\u201330.","journal-title":"J Prev Alzheimers Dis."},{"issue":"11","key":"1858_CR37","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/s10038-018-0494-z","volume":"63","author":"K Yamamoto","year":"2018","unstructured":"Yamamoto K, Shimizu A, Aizawa F, Kawame H, Tokutomi T, Fukushima A. A comparison of genome cohort participants\u2019 genetic knowledge and preferences to receive genetic results before and after a genetics workshop. J Hum Genet. 2018;63(11):1139\u201347.","journal-title":"J Hum Genet"},{"issue":"3","key":"1858_CR38","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a038968","volume":"10","author":"B Biesecker","year":"2020","unstructured":"Biesecker B. Genetic counseling and the central tenets of practice. Cold Spring Harb Perspect Med. 2020;10(3): a038968.","journal-title":"Cold Spring Harb Perspect Med."},{"issue":"9","key":"1858_CR39","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1056\/NEJMc2111960","volume":"385","author":"B Dunn","year":"2021","unstructured":"Dunn B, Stein P, Temple R, Cavazzoni P. An appropriate use of accelerated approval\u2014aducanumab for Alzheimer\u2019s disease. N Engl J Med. 2021;385(9):856\u20137.","journal-title":"N Engl J Med"},{"issue":"5","key":"1858_CR40","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s43441-022-00430-z","volume":"56","author":"G Beakes-Read","year":"2022","unstructured":"Beakes-Read G, Neisser M, Frey P, Guarducci M. Analysis of FDA\u2019s accelerated approval program performance December 1992\u2013December 2021. Ther Innov Regul Sci. 2022;56(5):698\u2013703.","journal-title":"Ther Innov Regul Sci."},{"issue":"1","key":"1858_CR41","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40035-021-00258-x","volume":"10","author":"F Rofo","year":"2021","unstructured":"Rofo F, Buijs J, Falk R, Honek K, Lannfelt L, Lilja AM, et al. Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta. Transl Neurodegener. 2021;10(1):38.","journal-title":"Transl Neurodegener."},{"issue":"2","key":"1858_CR42","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.trci.2017.03.005","volume":"3","author":"CY Wang","year":"2017","unstructured":"Wang CY, Wang PN, Chiu MJ, Finstad CL, Lin F, Lynn S, et al. UB-311, a novel UBITh((R)) amyloid beta peptide vaccine for mild Alzheimer\u2019s disease. Alzheimers Dement (N Y). 2017;3(2):262\u201372.","journal-title":"Alzheimers Dement (N Y)."},{"key":"1858_CR43","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.sbi.2014.12.004","volume":"30","author":"AJ Doig","year":"2015","unstructured":"Doig AJ, Derreumaux P. Inhibition of protein aggregation and amyloid formation by small molecules. Curr Opin Struct Biol. 2015;30:50\u20136.","journal-title":"Curr Opin Struct Biol."},{"issue":"12","key":"1858_CR44","doi-asserted-by":"publisher","first-page":"6355","DOI":"10.3390\/ijms22126355","volume":"22","author":"M Tolar","year":"2021","unstructured":"Tolar M, Hey J, Power A, Abushakra S. Neurotoxic soluble amyloid oligomers drive Alzheimer\u2019s pathogenesis and represent a clinically validated target for slowing disease progression. Int J Mol Sci. 2021;22(12):6355\u201368.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1858_CR45","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s43441-021-00364-y","volume":"56","author":"DT Michaeli","year":"2022","unstructured":"Michaeli DT, Yagmur HB, Achmadeev T, Michaeli T. Valuation and returns of drug development companies: lessons for bioentrepreneurs and investors. Ther Innov Regul Sci. 2022;56(2):313\u201322.","journal-title":"Ther Innov Regul Sci."},{"issue":"3","key":"1858_CR46","first-page":"393","volume":"9","author":"J Delrieu","year":"2022","unstructured":"Delrieu J, Bateman RJ, Touchon J, Sabbagh M, Cummings J. The future of AD clinical trials with the advent of anti-amyloid therapies: an CTAD Task Force report. J Prev Alzheimers Dis. 2022;9(3):393\u20139.","journal-title":"J Prev Alzheimers Dis."},{"issue":"10","key":"1858_CR47","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0000000000012329","volume":"97","author":"JD Grill","year":"2021","unstructured":"Grill JD, Karlawish J. Implications of FDA approval of a first disease-modifying therapy for a neurodegenerative disease on the design of subsequent clinical trials. Neurology. 2021;97(10):496\u2013500.","journal-title":"Neurology"},{"key":"1858_CR48","doi-asserted-by":"crossref","unstructured":"Zhang Y, Salter A, Wallstr\u00f6m E, Cutter G, St\u00fcve O. Evolution of clinical trials in multiple sclerosis. Ther Adv Neurol Disord. 2019;12:1756286419826547.","DOI":"10.1177\/1756286419826547"},{"issue":"12","key":"1858_CR49","first-page":"1230","volume":"24","author":"DL Shaw","year":"2018","unstructured":"Shaw DL, Dhruva SS, Ross JS. Coverage of novel therapeutic agents by medicare prescription drug plans following FDA approval. J Manag Care Spec Pharm. 2018;24(12):1230\u20138.","journal-title":"J Manag Care Spec Pharm"},{"issue":"10","key":"1858_CR50","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/jamaneurol.2022.2131","volume":"79","author":"AM Stern","year":"2022","unstructured":"Stern AM, Selkoe DJ. Unfairness to patients with Alzheimer disease in Medicare\u2019s coverage of antiamyloid immunotherapy. JAMA Neurol. 2022;79(10):962\u20133.","journal-title":"JAMA Neurol"},{"issue":"5","key":"1858_CR51","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/jamaneurol.2022.0315","volume":"79","author":"EL Ross","year":"2022","unstructured":"Ross EL, Weinberg MS, Arnold SE. Cost-effectiveness of aducanumab and donanemab for early Alzheimer disease in the US. JAMA Neurol. 2022;79(5):478\u201387.","journal-title":"JAMA Neurol"},{"issue":"8","key":"1858_CR52","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/s43587-022-00269-x","volume":"2","author":"H Hampel","year":"2022","unstructured":"Hampel H, Au R, Mattke S, van der Flier WM, Aisen P, Apostolova L, et al. Designing the next-generation clinical care pathway for Alzheimer\u2019s disease. Nature Aging. 2022;2(8):692\u2013703.","journal-title":"Nature Aging."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01858-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01858-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01858-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T12:10:14Z","timestamp":1686226214000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01858-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,15]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1858"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01858-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,15]]},"assertion":[{"value":"5 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JC is supported by NIGMS grant P20GM109025; NINDS grant U01NS093334; NIA grant R01AG053798; NIA grant P20AG068053; NIA grant P30AG072959; NIA grant R35AG71476; Alzheimer\u2019s Disease Drug Discovery Foundation (ADDF); Ted and Maria Quirk Endowment; and the Joy Chambers-Grundy Endowment. No payment was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"JC has provided recent (past year) consultation to Acadia, Actinogen, Acumen, AlphaCognition, AriBio, Artery, Biogen, Cassava, Cerecin, Corium, Diadem, EIP Pharma, Eisai, Genentech, GAP Innovations, Janssen, Karuna, Lilly, Lundbeck, LSP, Merck, NervGen, Novo Nordisk, Oligomerix, Optoceutics, Otsuka, PRODEO, Prothena, ReMYND, Resverlogix, Roche, Signant Health, Simcere, Sunbird Bio, Suven, TrueBinding, and Vaxxinity pharmaceutical, assessment, and investment companies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Dr. Cummings is the sole author and responsible for all aspects of the document.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}